CRIS Current Research Information System

TASSINARI, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.320
NA - Nord America 990
EU - Europa 683
SA - Sud America 136
AF - Africa 83
Continente sconosciuto - Info sul continente non disponibili 74
Totale 4.286
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 940
SG - Singapore 660
CN - Cina 610
VN - Vietnam 447
IT - Italia 309
HK - Hong Kong 196
KR - Corea 158
NL - Olanda 105
BR - Brasile 95
BD - Bangladesh 94
IN - India 54
DE - Germania 45
FR - Francia 42
CA - Canada 32
CI - Costa d'Avorio 32
JP - Giappone 31
FI - Finlandia 27
GB - Regno Unito 26
SC - Seychelles 23
ZA - Sudafrica 21
SE - Svezia 20
CH - Svizzera 18
RU - Federazione Russa 18
IE - Irlanda 17
AR - Argentina 16
AT - Austria 16
PH - Filippine 13
JO - Giordania 12
BG - Bulgaria 11
PL - Polonia 10
TH - Thailandia 9
CL - Cile 8
ID - Indonesia 7
LT - Lituania 6
PK - Pakistan 5
TR - Turchia 5
VE - Venezuela 5
CO - Colombia 4
EC - Ecuador 4
MX - Messico 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
ES - Italia 3
JM - Giamaica 3
NI - Nicaragua 3
SA - Arabia Saudita 3
TW - Taiwan 3
DZ - Algeria 2
GP - Guadalupe 2
HN - Honduras 2
IL - Israele 2
IQ - Iraq 2
UY - Uruguay 2
UZ - Uzbekistan 2
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EG - Egitto 1
ET - Etiopia 1
GT - Guatemala 1
IR - Iran 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LC - Santa Lucia 1
MA - Marocco 1
MK - Macedonia 1
ML - Mali 1
OM - Oman 1
PE - Perù 1
PT - Portogallo 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
TN - Tunisia 1
UA - Ucraina 1
Totale 4.212
Salva come PNG Salva come JPEG
Città #
Singapore 483
Hefei 282
Hong Kong 180
Ashburn 171
Seoul 154
San Jose 131
Ho Chi Minh City 118
Hanoi 114
Santa Clara 61
Council Bluffs 55
Bologna 54
Beijing 42
Boardman 40
Los Angeles 40
New York 36
Milan 34
Abidjan 32
Bengaluru 26
Da Nang 24
Dallas 23
São Paulo 23
Buffalo 21
Tokyo 20
Guangzhou 19
Johannesburg 19
Helsinki 18
Castel Maggiore 17
Dublin 17
Redondo Beach 17
Lauterbourg 16
Haiphong 15
Rome 13
Amman 12
Amsterdam 12
Bern 12
Nuremberg 12
Frankfurt am Main 11
Sofia 11
Vienna 11
Tongling 10
Turin 10
Falkenstein 9
Hyderabad 9
Biên Hòa 8
Chicago 8
Montreal 8
Munich 8
Warsaw 8
Brooklyn 7
Chennai 7
Columbus 7
Lappeenranta 7
Modena 6
Ninh Bình 6
Rimini 6
Zhengzhou 6
Atlanta 5
Bari 5
Florence 5
Jakarta 5
London 5
Moscow 5
Paris 5
Quận Bình Thạnh 5
San Francisco 5
Shanghai 5
Thái Nguyên 5
Toronto 5
Trieste 5
Xi'an 5
Boston 4
Changsha 4
Chengdu 4
Genoa 4
Houston 4
Hải Dương 4
Mexico City 4
Nanjing 4
Orem 4
Phoenix 4
Phú Thọ 4
Stockholm 4
Thái Bình 4
Tianjin 4
Tân Tiến 4
Zola Predosa 4
Belo Horizonte 3
Bắc Ninh 3
City of London 3
Enschede 3
Huế 3
Long Xuyen 3
Managua 3
Manchester 3
Manila 3
New Delhi 3
Omaha 3
Perugia 3
Phủ Lý 3
Queens 3
Totale 2.702
Salva come PNG Salva come JPEG
Nome #
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy 282
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 234
Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience 212
Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report 186
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 180
Dual-energy spectral CT in renal cell carcinoma: dawn of a brand-new era? 179
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes 177
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 177
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives 174
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 168
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 165
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 156
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 154
The value of molecular features in predicting efficacy of immuno-combinations in kidney cancer: just a drop in the ocean? 152
Appropriateness of Mini-Invasive Approaches for Nausea and Vomiting Refractory to Medical Therapy in Palliative Care Setting: A Case Report 141
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 137
The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis 127
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 108
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges 103
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 96
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 84
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 83
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 79
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma? 78
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 77
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? 75
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 73
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 72
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 69
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study 68
Pathological and Clinical Implications of Tumor Microenvironment Evaluated With Multiplex Immunohistochemistry in Testicular Embryonal Carcinoma 67
Advancements of investigational agents for renal cell carcinoma: what clinical progress have we seen in the last 5 years? 57
Prostate cancer and novel pharmacological treatment options - what's new for 2022? 55
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial 41
Totale 4.286
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.783
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.783
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023137 0 0 0 0 14 3 8 5 39 11 25 32
2023/2024155 10 18 13 8 14 29 4 15 11 5 18 10
2024/20251.026 44 85 60 49 80 42 52 43 17 97 198 259
2025/20262.832 303 368 264 244 246 81 342 82 405 173 148 176
2026/2027136 79 57 0 0 0 0 0 0 0 0 0 0
Totale 4.286